Revolutionising Biopharmaceutical Delivery: Market Insights

Subcutaneously (SC) administered pharmaceuticals offer several advantages over intravenous (IV) agents. Currently, eight of the ten top-selling pharmaceutical agents are available in SC formulations, with many featuring convenient self-injection devices.

The demand for new high-dose, chronically administered, injectable drugs is driving the development of unique, user-friendly, large-volume SC delivery systems. This presentation will outline the characteristics and dosing requirements of the future large-volume SC pipeline (LVSCs) and showcase innovative delivery approaches to facilitate the transition from IV to SC for both healthcare professionals (HCP) and self-administration.

Key topics include:

• An up-to-date overview of the surge in approved and pipeline LVSCs

• An exploration of the reasons behind the increase in high-dose/large volume injectables

• An overview of approved and development stage delivery technology to meet the needs

• Remaining barriers to IV to SC switching along with key questions

• Predictions for the future!